George Church argues that the primary barrier to advancing multiplex gene editing wasn't a specific technological breakthrough like CRISPR, but rather the imagination to find medically and ecologically significant applications for pre-existing capabilities.
Radical enhancements for cognition or longevity will likely be adopted by healthy people only after they are first developed and FDA-approved as therapies for specific diseases, like Alzheimer's. Competitive pressures will then drive widespread use, similar to obesity drugs.
George Church envisions a future where, in emergencies, millions of barcoded gene therapies could be tested simultaneously in one patient. This approach combines high-throughput synthesis with in-vivo testing to achieve nearly 100% accuracy by using a real human biological system.
George Church calculates that spending ~$100 to sequence a citizen's genome yields a $10k-$100k return. This massive ROI comes from avoiding the ~$1 million lifetime cost of caring for the 3% of children born with severe Mendelian diseases, a benefit realized within two years.
By sequencing 80% of its citizens, the UAE is poised to become the world's expert in applied genomics. This proactive public health initiative will not only relieve its disease burden but also establish it as a global leader that other nations, including the U.S., will eventually turn to for expertise.
Rather than confronting uncomfortable terms like "human enhancement," society adopts radical new technologies like vaccines or smartphones and simply redefines them as normal. People vote with their wallets for useful products long before they win an ethical debate, making the debate itself moot.
AI's impact isn't one magic bullet. It will accelerate drug discovery by enhancing multiple stages simultaneously: biasing protein drug candidates to fold correctly, improving their targeting and stability, and enabling the synthesis and testing of massive libraries in parallel. This multi-pronged optimization will create an exponential effect.
George Church predicts that reversing aging via somatic gene therapy will be the first truly mainstream genetic enhancement. Since aging will affect 90% of the population, therapies that restore youthful function in the elderly will have a massive impact and widespread adoption, becoming the "GLP-1 moment" for gene editing.
George Church bypasses the typical ethical debate, arguing germline editing faces three key business challenges: it doesn't apply to the 8 billion people already alive, clinical trials for late-onset diseases would take 80+ years, and it lacks a clear application not solvable by other means.
George Church compares financially failed genomics companies to the dot-com bubble. While investors may have lost money, these ventures built crucial technology and datasets that advanced the entire field for society's ultimate benefit, similar to how the dot-com bust left behind essential fiber optic networks.